Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / PSP Research LLC
Form 13F · Q2 2026

PSP Research LLC

CIK 2106939Filed 2026-07-0913F-HR View the filing on EDGAR ↗
$188M
Reported book value
75
Positions
3
Quarters on record
Top 50
Positions

PSP Research LLC — holdings

Top 50 positions of 75, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1SPDR SERIES TRUST Spdr Series Trust570,000+100.1%$90M48.0%
2ISHARES TR Ishares Tr700,000+0.0%$70M37.5%
3RPRX Royalty Pharma Plc11,000+0.0%$616,7700.3%
4NRIX Nurix Therapeutics Inc25,000−12.9%$606,5000.3%
5INCY Incyte Corp5,300+0.0%$600,8080.3%
6ARGX Argenx Se641+0.0%$594,7010.3%
7IRON Disc Medicine Inc8,000+0.0%$585,1200.3%
8RAPP Rapport Therapeutics Inc14,000+0.0%$583,3800.3%
9RARE Ultragenyx Pharmaceutical In17,000−23.1%$567,6300.3%
10TRVI Trevi Therapeutics Inc30,000+0.0%$559,5000.3%
11GLUE Monte Rosa Therapeutics Inc23,000−17.9%$556,6000.3%
12TGTX Tg Therapeutics Inc10,000−23.1%$549,4000.3%
13HALO Halozyme Therapeutics Inc7,000−12.8%$547,8900.3%
14IONS Ionis Pharmaceuticals Inc6,800+0.0%$539,1720.3%
15PHVS Pharvaris N V15,000−25.0%$518,7000.3%
16ARQT Arcutis Biotherapeutics Inc19,700+0.0%$516,5340.3%
17AUPH Aurinia Pharmaceuticals Inc30,000+0.0%$509,1000.3%
18NBIX Neurocrine Biosciences Inc3,000−22.0%$505,6050.3%
19IMVT Immunovant Inc13,000−32.3%$500,8900.3%
20ACAD Acadia Pharmaceuticals Inc19,766+0.0%$500,0800.3%
21PTCT Ptc Therapeutics Inc6,000+0.0%$489,4200.3%
22CLDX Celldex Therapeutics Inc New13,000+0.0%$483,7300.3%
23IMCR Immunocore Hldgs Plc15,141+0.0%$480,7270.3%
24DFTX Definium Therapeutics Inc10,000−71.3%$470,4000.3%
25COGT Cogent Biosciences Inc12,000+0.0%$464,4000.2%
26KYMR Kymera Therapeutics Inc4,000−36.5%$458,6800.2%
27DYN Dyne Therapeutics Inc20,000+0.0%$444,2000.2%
28ALNY Alnylam Pharmaceuticals Inc1,465+0.0%$441,0090.2%
29TARS Tarsus Pharmaceuticals Inc7,000+0.0%$440,5800.2%
30SNDX Syndax Pharmaceuticals Inc20,000+0.0%$437,2000.2%
31EXEL Exelixis Inc8,000−33.0%$435,2800.2%
32CRINETICS PHARMACEUTICALS IN Crinetics Pharmaceuticals In11,000+0.0%$411,6200.2%
33NAMS Newamsterdam Pharma Company12,000−20.0%$406,6800.2%
34ASND Ascendis Pharma A/S1,500—$400,0800.2%
35LQDA Liquidia Corporation5,000—$398,6500.2%
36STOK Stoke Therapeutics Inc12,000+0.0%$392,6400.2%
37VKTX Viking Therapeutics Inc10,000−33.3%$390,1000.2%
38IMNM Immunome Inc18,000−10.0%$381,4200.2%
39PTGX Protagonist Therapeutics Inc3,000+0.0%$367,7400.2%
40HRMY Harmony Biosciences Hldgs In10,000−30.0%$364,1000.2%
41ELVN Enliven Therapeutics Inc7,000+0.0%$355,2500.2%
42SYRE Spyre Therapeutics Inc4,000−22.5%$355,1200.2%
43NTLA Intellia Therapeutics Inc20,000−25.7%$338,4000.2%
44MDGL Madrigal Pharmaceuticals Inc600+0.0%$322,1700.2%
45KNSA Kiniksa Pharmaceuticals Intl5,000−44.4%$319,7500.2%
46ALKS Alkermes Plc6,000+0.0%$314,3700.2%
47TNGX Tango Therapeutics Inc10,000−30.6%$312,6000.2%
48ARDX Ardelyx Inc60,000−25.0%$306,0000.2%
49VERA Vera Therapeutics Inc7,000−30.0%$300,3700.2%
50MIRM Mirum Pharmaceuticals Inc2,500−50.0%$292,6750.2%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.